RBC Capital Maintains Outperform on Intra-Cellular Therapies, Lowers Price Target to $106
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Intra-Cellular Therapies (NASDAQ:ITCI) but lowers the price target from $107 to $106.
August 08, 2024 | 7:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Intra-Cellular Therapies but lowers the price target from $107 to $106.
The Outperform rating suggests continued confidence in the stock's performance, but the slight reduction in the price target may indicate minor concerns or adjustments in valuation. Overall, the impact is neutral as the rating remains positive.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100